


SWISS BIOTECH SUCCESS STORY



ESBATEch (now ESBATEch – a Novartis company) is recognized for its pioneering role of developing single-chain antibody fragments, in particular for ophthalmic indications.

ESBATEch was founded in 1998 and developed a novel technology for therapeutic applications of antibody fragments. The company raised in total USD 90M venture capital through Series A & B funding rounds. The USD 50M raised in the Series B round of 2006 was one of the largest financing rounds at that time for a preclinical stage biotech company.

Some 11 years after its founding, ESBATEch sold its ophthalmic business for USD 589M to Alcon, the leader in eye care. Shortly thereafter, Alcon was acquired by Novartis. The rise to prominence and success of ESBATEch's sale to Alcon can be attributed to the determined innovation and lasting impact of the company's entire team under Dominik Escher.



CEO



Dominik Escher
Co-founder and CEO
from 1998 to 2016




KNOWLEDGE

- Single-chain antibodies (scFv) were first described 1988, 32 years ago.
 - At that time, due to its small size compared to an antibody, the format was regarded as highly attractive for therapeutic applications.
- Many scFvs were in preclinical development and some in clinical development.
 - All failed, mainly due to stability, aggregation and manufacturing issues.
 - ESBATEch developed a novel technology to identify highly stable and soluble scFvs.




INDICATIONS

Beovu® (brolucizumab) received market approval by the FDA in October 2019 and is now also approved in Australia, Europe (EMA approval granted February 2020) and several Asian countries for the treatment of wet age-related macular degeneration. Beovu is the first scFv to come to market. It is also in phase 3 for diabetic eye diseases such as diabetic retinopathy.



STRUCTURE OF BEOVU® (brolucizumab)



Rabbit scFv
Humanized scFv1
Brolucizumab

SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Scientific breakthrough
- ★ New technology
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen
- ★ Swiss-based company
- ★ Swissness: Think global, made in Switzerland